【丁香园】已监测 7 例新冠变异株 JN.1，可能成为优势流行株：国家疾控局最新通报
近日，据国家疾控局信息，自 11 月首次发现本土 JN.1 变异株以来，截至 12 月 10 日，在我国本土病例中共监测到 7 例 JN.1 变异株，不排除成为国内优势流行株的可能。今年 11 月以来
Crossover Study Highlights Pharmacokinetic Effects of DHE Powder STS101
A recently published, randomized, open-label, 5-period crossover study showed that treatment with STS101, an intranasal dihydroergotamine (DHE) powder, was safe in healthy particip...
Closing Thoughts and Outlook of PD Care
At the 2024 American Academy of Neurology Annual Meeting, NeurologyLive® sat down with Parkinson disease (PD) expert Daniel Kremens, MD, JD, to discuss some of the top data being ...
【丁香园】985 博士实操比不过本科生！站友：临床水平和学历成正比吗？
行业动态版达人 @唐医生来了 在丁香园社区发帖称：你能想象一个 985 名牌大学的临床博士生连基本的手术打结都不会，手术操作甚至不如本科生吗？这就是近来，科室里来了个 985 博士，他的表现，...
Patient Death Reported in Phase 2 DAYLIGHT Study of Pfizer’s Gene Therapy for Duchenne
A patient in the phase 2 DALIGHT trial (NCT05429372) assessing Pfizer’s investigational gene therapy fordadistrogene movaparvovec (PF-06939926) in boys with Duchenne muscular dyst...
Criteria for Changing Treatment in Narcolepsy: Part 1
This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.Experts discu...
Criteria for Changing Treatment in Narcolepsy: Part 2
This is a video synopsis/summary of a panel discussion involving Michael Thorpy, MD; Karl Doghramji, MD, FAASM, DFAPA; Clete Kushida, MD, PhD; and Richard K Bogan, MD.The discussio...
Overlooked Neurological Features Present in Long COVID: Svetlana Blitshteyn, MD, FAAN
WATCH TIME: 3 minutes'For many years, those of us who specialize in these disorders have seen patients with very similar features that the patients with Long COVID have. Many of th...
NeurologyLive® Brain Games: May 12, 2024
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topi...
PrimeC Performs Well in High-Risk ALS, Patient Death Reported in DAYLIGHT Trial, Donanemab AdComm Hearing Date Announced
WATCH TIME: 4 minutesWelcome to this special edition of Neurology News Network. I’m Marco Meglio.Newly announced analyses from the phase 2b PARADIGM trial showed that treatment wi...
